Which has preferable earnings and valuation, BVS or LIVN?

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 1.96 $22.73M $0.77 17.61 LivaNova $1.39B 3.03 -$242.47M $3.38 22.59

Is BVS or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 9.36% 28.08% 9.82% LivaNova 12.82% 16.35% 7.76%

Does the media prefer BVS or LIVN?

In the previous week, LivaNova had 6 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for LivaNova and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat LivaNova's score of 0.79 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, BVS or PLSE?

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $581.85M 1.96 $22.73M $0.77 17.61 Pulse Biosciences $350K 9,818.95 -$72.78M -$1.18 N/A

Does the media prefer BVS or PLSE?

In the previous week, Pulse Biosciences had 7 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat Pulse Biosciences' score of 0.29 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IRTC or BVS?

In the previous week, iRhythm Technologies had 5 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for iRhythm Technologies and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat iRhythm Technologies' score of 0.19 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRhythm Technologies 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TMDX or BVS?

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 4.52 $190.29M $3.89 20.34 Bioventus $581.85M 1.96 $22.73M $0.77 17.61

Does the media favor TMDX or BVS?

In the previous week, TransMedics Group had 8 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for TransMedics Group and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat TransMedics Group's score of 0.64 indicating that Bioventus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ATRC or BVS?

Bioventus has higher revenue and earnings than AtriCure. Bioventus is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.41 -$11.45M $0.21 270.81 Bioventus $581.85M 1.96 $22.73M $0.77 17.61

Is ATRC or BVS more profitable?

Bioventus has a net margin of 9.36% compared to AtriCure's net margin of 1.85%. Bioventus' return on equity of 28.08% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Bioventus 9.36% 28.08% 9.82%

Does the media prefer ATRC or BVS?

In the previous week, AtriCure had 2 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for AtriCure and 3 mentions for Bioventus. AtriCure's average media sentiment score of 1.12 beat Bioventus' score of 1.08 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bioventus (BVS) Competitors

$13.51 -0.05 (-0.36%)

As of 11:41 AM Eastern

Compare

BVS vs. LIVN, PLSE, IRTC, TMDX, and ATRC

Should you buy Bioventus stock or one of its competitors? Bioventus's main competitors and comparable companies include LivaNova (LIVN), Pulse Biosciences (PLSE), iRhythm Technologies (IRTC), TransMedics Group (TMDX), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bioventus compare to LivaNova?

Bioventus (NASDAQ:BVS) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, LivaNova had 6 more articles in the media than Bioventus. MarketBeat recorded 9 mentions for LivaNova and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat LivaNova's score of 0.79 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Bioventus has higher earnings, but lower revenue than LivaNova. Bioventus is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	1.96	$22.73M	$0.77	17.61
LivaNova	$1.39B	3.03	-$242.47M	$3.38	22.59

Bioventus presently has a consensus price target of $16.80, suggesting a potential upside of 23.89%. LivaNova has a consensus price target of $87.75, suggesting a potential upside of 14.90%. Given Bioventus' stronger consensus rating and higher possible upside, analysts plainly believe Bioventus is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

LivaNova has a net margin of 12.82% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
LivaNova	12.82%	16.35%	7.76%

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 33.5% of Bioventus shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats Bioventus on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to Pulse Biosciences?

Bioventus (NASDAQ:BVS) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Bioventus currently has a consensus target price of $16.80, suggesting a potential upside of 23.89%. Pulse Biosciences has a consensus target price of $60.20, suggesting a potential upside of 24.02%. Given Pulse Biosciences' higher probable upside, analysts clearly believe Pulse Biosciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 33.5% of Bioventus shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bioventus has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

In the previous week, Pulse Biosciences had 7 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for Pulse Biosciences and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat Pulse Biosciences' score of 0.29 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has a net margin of 9.36% compared to Pulse Biosciences' net margin of -6,755.78%. Bioventus' return on equity of 28.08% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Bioventus has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$581.85M	1.96	$22.73M	$0.77	17.61
Pulse Biosciences	$350K	9,818.95	-$72.78M	-$1.18	N/A

Summary

Bioventus beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

How does Bioventus compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

iRhythm Technologies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

62.9% of Bioventus shares are owned by institutional investors. 1.0% of iRhythm Technologies shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Bioventus has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	4.75	-$44.55M	-$0.43	N/A
Bioventus	$581.85M	1.96	$22.73M	$0.77	17.61

In the previous week, iRhythm Technologies had 5 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for iRhythm Technologies and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat iRhythm Technologies' score of 0.19 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRhythm Technologies presently has a consensus price target of $178.79, suggesting a potential upside of 65.99%. Bioventus has a consensus price target of $16.80, suggesting a potential upside of 23.89%. Given iRhythm Technologies' higher possible upside, research analysts clearly believe iRhythm Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bioventus has a net margin of 9.36% compared to iRhythm Technologies' net margin of -1.69%. Bioventus' return on equity of 28.08% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Bioventus	9.36%	28.08%	9.82%

Summary

Bioventus beats iRhythm Technologies on 9 of the 17 factors compared between the two stocks.

How does Bioventus compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

TransMedics Group has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

In the previous week, TransMedics Group had 8 more articles in the media than Bioventus. MarketBeat recorded 11 mentions for TransMedics Group and 3 mentions for Bioventus. Bioventus' average media sentiment score of 1.08 beat TransMedics Group's score of 0.64 indicating that Bioventus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TransMedics Group has a net margin of 22.69% compared to Bioventus' net margin of 9.36%. Bioventus' return on equity of 28.08% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Bioventus	9.36%	28.08%	9.82%

TransMedics Group has higher revenue and earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.52	$190.29M	$3.89	20.34
Bioventus	$581.85M	1.96	$22.73M	$0.77	17.61

TransMedics Group presently has a consensus target price of $115.60, suggesting a potential upside of 46.07%. Bioventus has a consensus target price of $16.80, suggesting a potential upside of 23.89%. Given TransMedics Group's higher probable upside, equities analysts plainly believe TransMedics Group is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 33.5% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TransMedics Group beats Bioventus on 10 of the 16 factors compared between the two stocks.

How does Bioventus compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Bioventus (NASDAQ:BVS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

AtriCure presently has a consensus price target of $54.10, suggesting a potential downside of 4.87%. Bioventus has a consensus price target of $16.80, suggesting a potential upside of 23.89%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Bioventus has higher revenue and earnings than AtriCure. Bioventus is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.41	-$11.45M	$0.21	270.81
Bioventus	$581.85M	1.96	$22.73M	$0.77	17.61

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 33.5% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, AtriCure had 2 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for AtriCure and 3 mentions for Bioventus. AtriCure's average media sentiment score of 1.12 beat Bioventus' score of 1.08 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Bioventus has a net margin of 9.36% compared to AtriCure's net margin of 1.85%. Bioventus' return on equity of 28.08% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Bioventus	9.36%	28.08%	9.82%

Summary

Bioventus beats AtriCure on 9 of the 16 factors compared between the two stocks.

Get Bioventus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BVS vs. The Competition

Export

Metric	Bioventus	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.14B	$5.52B	$7.25B	$13.04B
Dividend Yield	N/A	1.75%	2.52%	22.89%
P/E Ratio	17.55	25.48	275.44	25.51
Price / Sales	1.95	66.54	562.05	79.58
Price / Cash	10.61	32.25	77.16	53.04
Price / Book	4.90	5.81	10.64	6.00
Net Income	$22.73M	$146.14M	$3.49B	$380.50M
7 Day Performance	5.80%	-1.66%	-3.21%	-3.35%
1 Month Performance	2.67%	-4.35%	-7.65%	-6.23%
1 Year Performance	102.26%	0.80%	2.92%	-3.96%

Bioventus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BVS Bioventus	4.0254 of 5 stars	$13.51 -0.4%	$16.80 +24.3%	+106.4%	$1.14B	$581.85M	17.55	950
LIVN LivaNova	3.2423 of 5 stars	$76.39 +0.6%	$87.75 +14.9%	+47.5%	$4.18B	$1.39B	22.60	3,300
PLSE Pulse Biosciences	2.9945 of 5 stars	$53.81 +7.7%	$53.20 -1.1%	+180.1%	$3.54B	$350K	N/A	116	News Coverage Analyst Forecast Gap Up
IRTC iRhythm Technologies	3.6266 of 5 stars	$106.70 +4.0%	$178.79 +67.6%	-39.3%	$3.38B	$747.14M	N/A	2,400	Analyst Downgrade
TMDX TransMedics Group	4.065 of 5 stars	$77.87 -1.4%	$121.00 +55.4%	-29.2%	$2.73B	$605.49M	20.02	898	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BVS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bioventus (BVS) Competitors

BVS vs. LIVN, PLSE, IRTC, TMDX, and ATRC

How does Bioventus compare to LivaNova?

Summary

How does Bioventus compare to Pulse Biosciences?

Summary

How does Bioventus compare to iRhythm Technologies?

Summary

How does Bioventus compare to TransMedics Group?

Summary

How does Bioventus compare to AtriCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bioventus (BVS) Competitors

BVS vs. LIVN, PLSE, IRTC, TMDX, and ATRC

How does Bioventus compare to LivaNova?

Does the media prefer BVS or LIVN?

Which has more volatility and risk, BVS or LIVN?

Which has preferable earnings and valuation, BVS or LIVN?

Do analysts prefer BVS or LIVN?

Is BVS or LIVN more profitable?

Do insiders and institutionals hold more shares of BVS or LIVN?

Summary

How does Bioventus compare to Pulse Biosciences?

Do analysts prefer BVS or PLSE?

Do insiders & institutionals hold more shares of BVS or PLSE?

Which has more risk & volatility, BVS or PLSE?

Does the media prefer BVS or PLSE?

Is BVS or PLSE more profitable?

Which has stronger valuation and earnings, BVS or PLSE?

Summary

How does Bioventus compare to iRhythm Technologies?

Which has more volatility & risk, IRTC or BVS?

Do institutionals and insiders hold more shares of IRTC or BVS?

Which has better valuation & earnings, IRTC or BVS?

Does the media prefer IRTC or BVS?

Do analysts rate IRTC or BVS?

Is IRTC or BVS more profitable?

Summary

How does Bioventus compare to TransMedics Group?

Which has more risk & volatility, TMDX or BVS?

Does the media favor TMDX or BVS?

Is TMDX or BVS more profitable?

Which has preferable valuation & earnings, TMDX or BVS?

Do analysts recommend TMDX or BVS?

Do institutionals & insiders hold more shares of TMDX or BVS?

Summary

How does Bioventus compare to AtriCure?

Do analysts rate ATRC or BVS?

Which has preferable earnings & valuation, ATRC or BVS?

Do insiders & institutionals hold more shares of ATRC or BVS?

Does the media prefer ATRC or BVS?

Which has more volatility and risk, ATRC or BVS?

Is ATRC or BVS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVS vs. The Competition

Bioventus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools